



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Thomas HESTERKAMP *et al.*

Confirmation No.: 9143

Application No.: 10/595,930

Filed: May 26, 2006

For: DIAGNOSTIC AND THERAPEUTIC USE
OF THE HUMAN SGPL1 GENE AND
PROTEIN FOR NEURODEGENERATIVE
DISEASES

International Application No.
PCT/EP/2004/0133111

International Filing Date:
November 18, 2004

Examiner: To Be Assigned

Art Unit:: To be Assigned

Atty. Docket No. 37998-237377

Customer No.
26694
PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Documents B1-B3 and C1-C2 were cited in the International Search Report of the corresponding PCT application, to which the instant application claims priority. A copy of the International Search Report is also enclosed.

Copies of the documents are not being provided since copies are furnished directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

In view of the above, no further statement of relevance need be given and, as all requirements of 37 C.F.R. § 1.97 and § 1.98, and all official guidelines pertaining to Information Disclosure Statements have been complied with, it is respectfully requested that the Examiner consider the cited references and make them of record.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

It is believed that no fee is required for the submission of this Information Disclosure Statement; however, if a fee is determined to be due, please charge the amount to our Deposit Account No. 22-0261, and advise the undersigned accordingly.

Date: 3/2/2007

Respectfully submitted,

Kavita B. Lepping
Kavita B. Lepping
Registration No. 54,262
VENABLE, LLP
P.O. Box 34385
Washington, D.C. 20043-9998
Telephone: (202) 344-4000
Telefax : (202) 344-8300

KBL/kac
#832823

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/595,930 – Conf. No. 9143
Filing Date	May 26, 2006
First Named Inventor	Thomas HESTERKAMP
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	37998-237377

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office 3	Number ⁴	Code ⁵ (if known)				
	B1	WO	99/38983 A		SMITHKLINE BEECHAM PLC)	08-05-1999		
	B2	WO	02/22078 A		ATAIRGIN TECHNOLOGIES, INC.	03-21-2002		
	B3	WO	99/16888 A		CHILDREN'S HOSPITAL OAKLAND RESEARCH INSTITUTE; CHILDREN'S HOSPITAL, ME	04-08-1999		

OTHER PRIOR ART – PENDING PATENT APPLICATIONS

Examiner Initials *	Cite No. ¹		
	C1	"Identification of the First Mammalian Sphingosine Phosphate Lyase Gene and Its Functional Expression in Yeast," ZHOU, J. and SABA, J., <i>Biochemical and Biophysical Research Communications</i> , Vol. 242, pp. 502-507, 1998.	
	C2	"Aberrant sphingomyelin/ceramide metabolic-induced neuronal endosomal/lysosomal dysfunction: Potential pathological consequences in age-related neurodegeneration," SOREGHAN, Brian, et al., <i>Advanced Drug Delivery Reviews</i> , Vol. 55, No. 11, pp. 1515-1524, November 14, 2003.	

Examiner Signature

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

DC2DOCS1\831371